T Sekine1, K Masuko-Hongo, T Matsui, H Asahara, M Takigawa, K Nishioka, T Kato. 1. Rheumatology, Immunology and Genetics Programme, Institute of Medical Science, St Marianna University, School of Medicine 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8512, Japan.
Abstract
OBJECTIVE: To investigate whether autoimmunity to YKL-39, a recently cloned cartilage protein, occurs in patients with rheumatoid arthritis (RA). METHODS: Autoantibody to YKL-39 was assayed by enzyme linked immunosorbent assay (ELISA) and western blotting in serum samples from patients with RA, systemic lupus erythematosus (SLE), and healthy donors, using recombinant YKL-39 protein. This reactivity was compared with that against a YKL-39 homologue, YKL-40 (human cartilage gp-39/chondrex), which has been reported to be an autoantigen in RA. RESULTS: Autoantibody to YKL-39 was detected in seven of 87 patients with RA (8%), but not in serum samples from patients with SLE or healthy donors. YKL-40 reactivity was found in only one of 87 RA serum samples (1%), with no cross reactivity to YKL-39. CONCLUSION: The existence of anti-YKL-39 antibody in a subset of patients with RA is reported here for the first time. Further, it was shown that the immune response to YKL-39 was independent of that to YKL-40. Clarification of the antibody and T cell responses to autoantigens derived from chondrocyte, cartilage, or other joint components may lead to a better understanding of the pathophysiology of joint destruction in patients with RA.
OBJECTIVE: To investigate whether autoimmunity to YKL-39, a recently cloned cartilage protein, occurs in patients with rheumatoid arthritis (RA). METHODS: Autoantibody to YKL-39 was assayed by enzyme linked immunosorbent assay (ELISA) and western blotting in serum samples from patients with RA, systemic lupus erythematosus (SLE), and healthy donors, using recombinant YKL-39 protein. This reactivity was compared with that against a YKL-39 homologue, YKL-40 (humancartilagegp-39/chondrex), which has been reported to be an autoantigen in RA. RESULTS: Autoantibody to YKL-39 was detected in seven of 87 patients with RA (8%), but not in serum samples from patients with SLE or healthy donors. YKL-40 reactivity was found in only one of 87 RA serum samples (1%), with no cross reactivity to YKL-39. CONCLUSION: The existence of anti-YKL-39 antibody in a subset of patients with RA is reported here for the first time. Further, it was shown that the immune response to YKL-39 was independent of that to YKL-40. Clarification of the antibody and T cell responses to autoantigens derived from chondrocyte, cartilage, or other joint components may lead to a better understanding of the pathophysiology of joint destruction in patients with RA.
Authors: T Hattori; T Fujisawa; K Sasaki; Y Yutani; T Nakanishi; K Takahashi; M Takigawa Journal: Biochem Biophys Res Commun Date: 1998-04-28 Impact factor: 3.575
Authors: G F Verheijden; A W Rijnders; E Bos; C J Coenen-de Roo; C J van Staveren; A M Miltenburg; J H Meijerink; D Elewaut; F de Keyser; E Veys; A M Boots Journal: Arthritis Rheum Date: 1997-06
Authors: T Matsui; M Kurokawa; T Kobata; S Oki; M Azuma; S Tohma; T Inoue; K Yamamoto; K Nishioka; T Kato Journal: J Immunol Date: 1999-04-01 Impact factor: 5.422
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: Prakash Manikwar; Paul Kiptoo; Ahmed H Badawi; Barlas Büyüktimkin; Teruna J Siahaan Journal: Med Res Rev Date: 2011-03-23 Impact factor: 12.944
Authors: Carmelo Carmona-Rivera; Philip M Carlucci; Erica Moore; Nithya Lingampalli; Hannes Uchtenhagen; Eddie James; Yudong Liu; Kevin L Bicker; Heidi Wahamaa; Victoria Hoffmann; Anca Irinel Catrina; PaulR Thompson; Jane H Buckner; William H Robinson; David A Fox; Mariana J Kaplan Journal: Sci Immunol Date: 2017-04-14
Authors: Julia Kzhyshkowska; Alexandru Gudima; Kondaiah Moganti; Alexei Gratchev; Alexander Orekhov Journal: Transfus Med Hemother Date: 2016-03-15 Impact factor: 3.747